Metabolism of lysolecithin in vivo: effects of hyperlipemia and atherosclerosis in squirrel monkeys.
We have studied the effect of long-term hyperlipemia and atherosclerosis in squirrel monkeys on the metabolism of lysolecithin-(14)C (1-palmitoyl-1'-(14)C sn-glycerol 3-phosphorylcholine) in order to explain elevated plasma and arterial concentrations of lysolecithin. The die-away curves of lysolecithin-(14)C from plasma and the timing of appearances of other (14)C-labeled moieties in plasma and other tissues demonstrated a complex pattern of metabolic reactions. There was a rapid equilibration of specific activities of lysolecithin of plasma, liver, and aortic intima plus inner media. The specific activities of lecithin peaked first in liver, then in plasma, and rose slowly in aortic intima plus inner media. The appearance of lecithin-(14)C in heart and skeletal muscle was also slower than in the liver and some other tissues. Triglycerides, and to a lesser extent, cholesteryl esters contained radioactivity. The concentrations of aortic lysolecithin in the atherosclerotic aortas were several times greater than comparable values for control aortas, and the time of equilibration of plasma and aorta lysolecithin-(14)C was much greater for the atherosclerotic group. The quantities of lysolecithin in plasma and in the pool of which the plasma was a part, were increased with hyperlipemia and atherosclerosis, as was the rate of lysolecithin production in the fast pool. Hyperlipemia was also associated with an early increase in plasma lecithin:cholesterol acyltransferase (LCAT) activity in vitro. Furthermore, nutritional hyperlipemia influenced the distribution of lysolecithin-(14)C and lecithin-(14)C between different plasma lipoproteins. The increase in concentrations of lysolecithin in the aorta occurred more slowly than that in plasma after we had induced hyperlipemia in the monkeys.
D000217:Acyltransferases / Q000378:metabolism; D000818:Animals; D001011:Aorta / Q000032:analysis; D001161:Arteriosclerosis / Q000378:metabolism*; D002247:Carbon Isotopes; D002784:Cholesterol / Q000378:metabolism; D002855:Chromatography, Thin Layer; D004036:Diet, Atherogenic; D004952:Esters / Q000378:metabolism; D005260:Female; D000882:Haplorhini; D006949:Hyperlipidemias / Q000201:enzymology / Q000378:metabolism*; D007275:Injections, Intravenous; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D008244:Lysophosphatidylcholines / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D009132:Muscles / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D010713:Phosphatidylcholines / Q000032:analysis / Q000097:blood; D010740:Phospholipases; D013997:Time Factors; D014280:Triglycerides / Q000378:metabolism
D002247:Carbon Isotopes; D004952:Esters; D008244:Lysophosphatidylcholines; D010713:Phosphatidylcholines; D014280:Triglycerides; D002784:Cholesterol; D000217:Acyltransferases; D010740:Phospholipases